
In the EU, demonstrating safety and effectiveness is not a one-time task. Under the IVDR, clinical evidence must be continuously generated and re-evaluated, with a clear link to both state-of-the-art and risk management practices.
This article offers:
- A breakdown of the three key pillars of clinical evidence: scientific validity, analytical performance, and clinical performance
- Clear guidance on tailoring your approach based on device risk class and type
- Best practices for evaluating the state of the art and integrating it into your performance evaluation
- Clarification of postmarket performance follow-up (PMPF) requirements—and how they support your benefit-risk assessment
Whether you're compiling a performance evaluation report or refining your PMS and PMPF strategies, this article is a valuable resource for navigating EU IVDR compliance.

About the author

Pieter Bogaert
Senior Consultant IVD - Regulatory Affairs
Pieter Bogaert is a Regulatory Affairs Consultant and ISO 13485 Lead Auditor specializing in in vitro diagnostic medical devices (IVD). With expertise in European regulations, he supports IVD manufacturers, pharma and biotech companies, and EU laboratories in achieving compliance with the In Vitro Diagnostic Regulation (IVDR).
His consultancy covers regulatory strategy, quality management system compliance, risk management, performance evaluation, and technical documentation submissions. As Co-Chair of the RAPS Belgium Local Networking Group, Pieter actively contributes to the regulatory affairs community. With a background in biomedical sciences, he brings hands-on and managerial experience in medical laboratories, CE-marked IVDs, and in-house developed tests for clinical drug trials.

关于作者
PhD Biotechnology · Senior Consultant IVD – Regulatory Affairs
Pieter is a Senior IVD Regulatory Affairs Consultant at QbD Group, specializing in EU IVDR compliance, clinical evidence requirements, and regulatory strategy for diagnostic devices.
Navigate Regulatory Complexity with Confidence
Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.
Read more订阅生命科学领域的最新动态
专家观点直达您的收件箱——选择您的兴趣。
绝无垃圾邮件。随时取消订阅。


